Striverdi (olodaterol; Boehringer Ingelheim) is a long-acting beta 2 agonist delivered via the Respimat inhaler. It is indicated for the once-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD). Striverdi Respimat received US and EU approvals for use in COPD in July 2014 and October 2013, respectively. Datamonitor Healthcare is not aware of any specific development of olodaterol monotherapy in Japan and does not forecast the therapy for this market.
LIST OF FIGURES
9 Figure 1: Striverdi Respimat for COPD – SWOT analysis
10 Figure 2: Datamonitor Healthcare’s drug assessment summary of Striverdi Respimat for COPD
11 Figure 3: Datamonitor Healthcare’s drug assessment summary of Striverdi Respimat for COPD
13 Figure 4: Striverdi Respimat sales for COPD across the US and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Striverdi Respimat drug profile
7 Table 2: Striverdi Respimat Phase III data in COPD
14 Table 3: Striverdi Respimat sales for COPD across the US and five major EU markets, by country ($m), 2017–26
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.